Menu
← Oncology Approval Tracker
FDA DECISION ·
Zejula tablets
niraparib · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
New tablet presentation for maintenance after a response to first-line platinum in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, or after platinum response in recurrent disease with a qualifying germline BRCA alteration.
LAMPGEN ANALYSIS
Why it matters
The tablet approval covered first-line maintenance and a biomarker-restricted recurrent maintenance use.
What research teams should watch
Verify treatment setting, response to platinum and germline BRCA status where required, and reconcile capsule and tablet strengths.
PRIMARY RECORDS